Aprea Therapeutics

Aprea Therapeutics

Aprea Therapeutics was founded in 2003 by researchers investigating p53 tumor suppressor biology, initially focused on small-molecule reactivation of mutant p53. The company shifted its strategic focus in the early 2020s after Phase 3 failure of its lead asset eprenetapopt in myelodysplastic syndromes, pivoting to DDR-targeted therapies. Today, its pipeline is built around two clinical-stage assets acquired or developed in-house. The company's strategy centers on synthetic lethality — designing drugs that selectively kill cancer cells with specific genetic vulnerabilities while sparing normal tissue. Its lead program, ATRN-119, is a macrocyclic ATR kinase inhibitor in Phase 1/2 trials for solid tumors. A second asset, APR-1051, targets WEE1 and entered the clinic in 2024 under an IND cleared by the FDA. Preclinical work also explores combinations with PARP inhibitors and checkpoint antibodies. The geographic footprint is North America, with operations based in Pennsylvania. Aprea reported cash and equivalents of approximately $22 million at the end of 2023, with a workforce trimmed to fewer than 25 full-time employees following a restructuring announced in June 2023. This downsizing coincided with the discontinuation of legacy p53 programs and a narrowed focus on the DDR pipeline. The company maintains a Nasdaq listing under the ticker APRE and has historically funded operations through equity offerings and at-the-market facilities. The firm's structural differentiator lies in its condensed, post-pivot operating model — a micro-cap biotech that repositioned around assets acquired from other developers rather than conducting de novo preclinical discovery. This capital-efficient posture contrasts with discovery-heavy peers, with clinical execution outsourced to CROs and manufacturing partners while a lean internal team manages regulatory and IP strategy.